{"nctId":"NCT02361216","briefTitle":"Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest","startDateStruct":{"date":"2015-04"},"conditions":["Actinic Keratosis"],"count":729,"armGroups":[{"label":"Ingenol mebutate gel","type":"EXPERIMENTAL","interventionNames":["Drug: Ingenol Mebutate"]},{"label":"Vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Vehicle"]}],"interventions":[{"name":"Ingenol Mebutate","otherNames":[]},{"name":"Vehicle","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects with 5 to 20 clinically typical, visible and discrete, actinic keratosis (AKs) non-hyperkeratotic and non-hypertrophic AKs within a selected treatment area of sun-damaged skin on either:\n\n* The full face\n* The full balding scalp\n* A contiguous area of approximately 250 cm2 on the chest\n\nExclusion Criteria:\n\n* Location of the treatment area (full face, full balding scalp or chest) within 5 cm of an incompletely healed wound or within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC).\n* Previously assigned treatment in this clinical trial or previously participated in a clinical trial in the LEO clinical programme on ingenol mebutate gel for larger treatment areas.\n* Treatment with ingenol mebutate gel in the selected treatment area within the last 12 months.\n* Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous horn) and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions).","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Complete Resolution of Actinic Keratosis (AK)","description":"Complete resolution of actinic keratosis (AKclear100) at Week 8 is defined as 100% reduction from baseline in the number of clinically visible AKs","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","spread":null},{"groupId":"OG001","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Clearance at Week 8","description":"Partial clearance (AKclear75 ) is defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Partial Clearance at Week 4","description":"Partial clearance (AKclear75) defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null},{"groupId":"OG001","value":"9.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Reduction From Baseline in AK Count","description":"Percent reduction in AK count in the selected treatment area at Week 8","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.7","spread":null},{"groupId":"OG001","value":"12.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":549},"commonTop":["Application Site Pain","Application Site Pruritus","Application Site Discomfort","headache","application site parasthesia"]}}}